Allergan expands dry eye portfolio with launch of Refresh Optive Gel Drops
![](/46/pdcnewsitem/03/76/26/unnamed.jpg)
In a clinical study, patients report significant reduction in dry eye symptoms in just 30 days of usage.
Allergan has launched the over-the-counter artificial tear Refresh Optive Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms. From Refresh, the creators of the number one doctor recommended brand of artificial tears, new Refresh Optive Gel Drops are formulated with Glycerin and a unique blend of the active ingredient CMC which binds to the eye surface to provide long-lasting relief from Dry Eye discomfort.
"With Refresh Optive Gel Drops, eye care providers now have an even more comprehensive line of artificial tear types to offer to their patients with individual needs," said Joseph Vehige, O.D., Vice President of Consumer Eye Care Research & Development,Allergan. "Leveraging the latest technology from Optive, the new multi-dose Gel Drops help dry eye patients find comfort any time, day or night."
An estimated 25 million people in the US suffer from dry eye symptoms, including irritation, blurred vision, sensitivity to light, burning, stinging, dryness and excessive tearing. In a multicenter, double-masked, randomized study, dry eye patients (n=94) using Refresh Optive Gel Drops showed a statistically significant reduction in symptoms at day 30. The innovative Gel Drops formula delivers a shear-thinning effect that spreads quickly and evenly over the eye surface to relieve dry eye symptoms while creating a soothing shield to protect the eye surface from hypertonic stress.
"Dry eye is a reduction in your eyes' ability to produce or maintain sufficient quantity and quality of natural tears. Tears are important to the overall health of our eyes and our vision. My patients suffering from dry eye symptoms often ask me for a more hydrating artificial tear that will give them longer-lasting relief and comfort," said Milton M. Hom, OD, FAAO. "I like Refresh Optive Gel Drops because of its advanced aqueous gel formulation that helps the ocular surface maintain its moisture level. Refresh Optive products are effective in reducing dry eye symptoms and convenient to use with no shaking required — just drop and go."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance